One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Secatinib is an oral biologic that is a selective inhibitor of wild-type, mutant, and fusion products. It involves rearrangement of the oncogene receptor tyrosine kinase during transfection (RET) and has potential anti-tumor activity. After oral administration, secatinib can selectively bind to wild-type RET as well as various RET mutants and fusion products containing RET, and use them as targets. This will lead to inhibition of the growth of tumor cells exhibiting increased RET activity. In addition, secatinib can also target, bind, and inhibit vascular endothelial growth factor receptors 1 (VEGFR1) and 3 (VEGFR3), as well as fibroblast growth factor receptors 1 (FGFR1), 2 (FGFR2), and 3 (FGFR3). Overexpression, activation mutations, and fusion of RET lead to upregulation and/or overactivation of RET tyrosine kinase activity in various cancer cell types; The imbalance of RET activity plays a crucial role in the development and progression of these cancers.
One year of qualification
Audited Supplier
Pharma Sources Insight January 2025
